Natera, Inc. (NASDAQ:NTRA) Insider Sells $71,916.06 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Daniel Rabinowitz sold 787 shares of the firm's stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $71,916.06. Following the completion of the transaction, the insider now owns 205,552 shares of the company's stock, valued at $18,783,341.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Daniel Rabinowitz also recently made the following trade(s):

• On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The shares were sold at an average price of $89.01, for a total value of $1,827,019.26.
• On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total value of $2,651,202.63.

Natera Price Performance

NASDAQ NTRA traded up $2.43 during midday trading on Tuesday, hitting $91.04. The company had a trading volume of 1,178,233 shares, compared to its average volume of 1,470,075. The company has a market capitalization of $10.99 billion, a PE ratio of -24.02 and a beta of 1.37. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The firm has a 50-day moving average price of $86.40 and a 200-day moving average price of $66.49. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $98.82.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analysts' expectations of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. National Bank of Canada FI bought a new position in shares of Natera in the 3rd quarter valued at $1,932,000. CWM LLC increased its stake in shares of Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company's stock valued at $58,000 after purchasing an additional 911 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Natera by 1,503.2% in the 3rd quarter. SG Americas Securities LLC now owns 97,973 shares of the medical research company's stock valued at $4,335,000 after purchasing an additional 91,862 shares during the last quarter. Ellsworth Advisors LLC bought a new position in shares of Natera in the 3rd quarter valued at $364,000. Finally, Xponance Inc. increased its stake in shares of Natera by 1.8% in the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company's stock valued at $642,000 after purchasing an additional 261 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTRA has been the subject of several research analyst reports. StockNews.com downgraded Natera from a "hold" rating to a "sell" rating in a research note on Tuesday. Piper Sandler lifted their target price on Natera from $70.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 6th. Craig Hallum initiated coverage on Natera in a research note on Monday, April 8th. They set a "buy" rating and a $117.00 target price for the company. Canaccord Genuity Group lifted their target price on Natera from $87.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, February 29th. Finally, Stephens reiterated an "overweight" rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.